



## Clinical trial results:

**A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demonstrate efficacy after twelve weeks of treatment and to assess safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis with or without psoriatic arthritis comorbidity**

### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2016-000524-25   |
| Trial protocol           | HU               |
| Global end of trial date | 20 November 2018 |

### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1 (current)     |
| This version publication date  | 02 December 2019 |
| First version publication date | 02 December 2019 |

### Trial information

#### Trial identification

|                       |              |
|-----------------------|--------------|
| Sponsor protocol code | CAIN457A2318 |
|-----------------------|--------------|

#### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT03066609 |
| WHO universal trial number (UTN)   | -           |

Notes:

### Sponsors

|                              |                                                                                           |
|------------------------------|-------------------------------------------------------------------------------------------|
| Sponsor organisation name    | Novartis Pharmaceuticals                                                                  |
| Sponsor organisation address | CH4002, Basel, Switzerland,                                                               |
| Public contact               | Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com |
| Scientific contact           | Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com |

Notes:

### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |                  |
|------------------------------------------------------|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 20 November 2018 |
| Is this the analysis of the primary completion data? | No               |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 20 November 2018 |
| Was the trial ended prematurely?                     | No               |

Notes:

## General information about the trial

Main objective of the trial:

the main objective for this trial was to demonstrate the superiority of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis in terms of both PASI 75 and IGA mod 2011 0 or 1 response (co-primary endpoints) at Week 12 compared to placebo.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

|                                                           |                  |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment                          | 28 February 2017 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | Yes              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                 |
|--------------------------------------|-----------------|
| Country: Number of subjects enrolled | China: 441      |
| Country: Number of subjects enrolled | Hungary: 23     |
| Country: Number of subjects enrolled | Malaysia: 12    |
| Country: Number of subjects enrolled | Philippines: 18 |
| Country: Number of subjects enrolled | Thailand: 35    |
| Country: Number of subjects enrolled | Turkey: 14      |
| Worldwide total number of subjects   | 543             |
| EEA total number of subjects         | 23              |

Notes:

### Subjects enrolled per age group

|                                           |   |
|-------------------------------------------|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 0 |

|                           |     |
|---------------------------|-----|
| Children (2-11 years)     | 0   |
| Adolescents (12-17 years) | 0   |
| Adults (18-64 years)      | 531 |
| From 65 to 84 years       | 12  |
| 85 years and over         | 0   |

## Subject disposition

### Recruitment

Recruitment details:

A total of 664 patients were screened and 543 patients were randomized to one of three treatment groups in the induction period: secukinumab 300 mg (n=272), secukinumab 150 mg (n=136), and placebo (n=135)

### Pre-assignment

Screening details: -

### Pre-assignment period milestones

|                              |     |
|------------------------------|-----|
| Number of subjects started   | 543 |
| Number of subjects completed | 543 |

### Period 1

|                              |                                                               |
|------------------------------|---------------------------------------------------------------|
| Period 1 title               | INDUCTION                                                     |
| Is this the baseline period? | Yes                                                           |
| Allocation method            | Randomised - controlled                                       |
| Blinding used                | Double blind                                                  |
| Roles blinded                | Subject, Investigator, Monitor, Data analyst, Carer, Assessor |

### Arms

|                              |                   |
|------------------------------|-------------------|
| Are arms mutually exclusive? | Yes               |
| <b>Arm title</b>             | Secukinumab 150mg |

Arm description:

Secukinumab 150mg s.c.

|                                        |                                              |
|----------------------------------------|----------------------------------------------|
| Arm type                               | Experimental                                 |
| Investigational medicinal product name | Secukinumab                                  |
| Investigational medicinal product code | AIN457                                       |
| Other name                             |                                              |
| Pharmaceutical forms                   | Solution for injection in pre-filled syringe |
| Routes of administration               | Subcutaneous use                             |

Dosage and administration details:

Secukinumab 150 mg for subcutaneous injection was supplied in a 150 mg 1 mL pre-filled syringe.

|                  |                   |
|------------------|-------------------|
| <b>Arm title</b> | Secukinumab 300mg |
|------------------|-------------------|

Arm description:

Secukinumab 300mg s.c.

|                                        |                                              |
|----------------------------------------|----------------------------------------------|
| Arm type                               | Experimental                                 |
| Investigational medicinal product name | Secukinumab                                  |
| Investigational medicinal product code | AIN457                                       |
| Other name                             |                                              |
| Pharmaceutical forms                   | Solution for injection in pre-filled syringe |
| Routes of administration               | Subcutaneous use                             |

Dosage and administration details:

Secukinumab 150 mg for subcutaneous injection was supplied in a 150 mg 1 mL pre-filled syringe. two injections of the 150 mg dose

|                  |         |
|------------------|---------|
| <b>Arm title</b> | placebo |
|------------------|---------|

Arm description:

Placebo to secukinumab s.c

|          |         |
|----------|---------|
| Arm type | Placebo |
|----------|---------|

|                                        |                                              |
|----------------------------------------|----------------------------------------------|
| Investigational medicinal product name | placebo                                      |
| Investigational medicinal product code |                                              |
| Other name                             |                                              |
| Pharmaceutical forms                   | Solution for injection in pre-filled syringe |
| Routes of administration               | Subcutaneous use                             |

Dosage and administration details:

Secukinumab placebo for sc injection was supplied as a 1 mL pre-filled syringe matching the appearance of 150 mg secukinumab syringe

| Number of subjects in period 1 | Secukinumab 150mg | Secukinumab 300mg | placebo |
|--------------------------------|-------------------|-------------------|---------|
| Started                        | 136               | 272               | 135     |
| Completed                      | 134               | 270               | 133     |
| Not completed                  | 2                 | 2                 | 2       |
| Adverse event, non-fatal       | 2                 | 2                 | -       |
| Pregnancy                      | -                 | -                 | 1       |
| Lack of efficacy               | -                 | -                 | 1       |

## Period 2

|                              |                                                               |
|------------------------------|---------------------------------------------------------------|
| Period 2 title               | MAINTENANCE                                                   |
| Is this the baseline period? | No                                                            |
| Allocation method            | Randomised - controlled                                       |
| Blinding used                | Double blind                                                  |
| Roles blinded                | Subject, Investigator, Monitor, Data analyst, Carer, Assessor |

## Arms

|                              |                   |
|------------------------------|-------------------|
| Are arms mutually exclusive? | Yes               |
| <b>Arm title</b>             | Secukinumab 150mg |

Arm description:

Secukinumab 150mg s.c.

|                                        |                                              |
|----------------------------------------|----------------------------------------------|
| Arm type                               | Experimental                                 |
| Investigational medicinal product name | Secukinumab                                  |
| Investigational medicinal product code | AIN457                                       |
| Other name                             |                                              |
| Pharmaceutical forms                   | Solution for injection in pre-filled syringe |
| Routes of administration               | Subcutaneous use                             |

Dosage and administration details:

Secukinumab 150 mg for subcutaneous injection was supplied in a 150 mg 1 mL pre-filled syringe.

|                  |                   |
|------------------|-------------------|
| <b>Arm title</b> | Secukinumab 300mg |
|------------------|-------------------|

Arm description:

Secukinumab 300mg s.c.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|                                        |                                              |
|----------------------------------------|----------------------------------------------|
| Investigational medicinal product name | Secukinumab                                  |
| Investigational medicinal product code | AIN457                                       |
| Other name                             |                                              |
| Pharmaceutical forms                   | Solution for injection in pre-filled syringe |
| Routes of administration               | Subcutaneous use                             |

Dosage and administration details:

Secukinumab 150 mg for subcutaneous injection was supplied in a 150 mg 1 mL pre-filled syringe. two injections of the 150 mg dose

|                  |                   |
|------------------|-------------------|
| <b>Arm title</b> | placebo - placebo |
|------------------|-------------------|

Arm description:

Placebo patients who remained on Placebo after week 12

|                                        |                                              |
|----------------------------------------|----------------------------------------------|
| Arm type                               | Placebo                                      |
| Investigational medicinal product name | placebo                                      |
| Investigational medicinal product code |                                              |
| Other name                             |                                              |
| Pharmaceutical forms                   | Solution for injection in pre-filled syringe |
| Routes of administration               | Subcutaneous use                             |

Dosage and administration details:

Secukinumab placebo for sc injection was supplied as a 1 mL pre-filled syringe matching the appearance of 150 mg secukinumab syringe

|                  |                             |
|------------------|-----------------------------|
| <b>Arm title</b> | Placebo - secukinumab 300mg |
|------------------|-----------------------------|

Arm description:

patients switched to Secukinumab (AIN457) at week 12

|                                        |                                              |
|----------------------------------------|----------------------------------------------|
| Arm type                               | placebo switched to experimental             |
| Investigational medicinal product name | Secukinumab                                  |
| Investigational medicinal product code | AIN457                                       |
| Other name                             |                                              |
| Pharmaceutical forms                   | Solution for injection in pre-filled syringe |
| Routes of administration               | Subcutaneous use                             |

Dosage and administration details:

Secukinumab 150 mg for subcutaneous injection was supplied in a 150 mg 1 mL pre-filled syringe. 2 injections of 150 mg. Switch after placebo for 12 weeks.

| <b>Number of subjects in period 2</b> | Secukinumab 150mg | Secukinumab 300mg | placebo - placebo |
|---------------------------------------|-------------------|-------------------|-------------------|
| Started                               | 134               | 270               | 4                 |
| Completed                             | 127               | 266               | 2                 |
| Not completed                         | 7                 | 4                 | 2                 |
| Adverse event, non-fatal              | -                 | -                 | -                 |
| Pregnancy                             | 1                 | -                 | -                 |
| Subject or guardian decision          | 4                 | 2                 | 1                 |
| Lost to follow-up                     | -                 | 1                 | 1                 |
| Lack of efficacy                      | 2                 | 1                 | -                 |

| <b>Number of subjects in period 2</b> | Placebo - secukinumab 300mg |
|---------------------------------------|-----------------------------|
| Started                               | 129                         |

|                              |     |
|------------------------------|-----|
| Completed                    | 126 |
| Not completed                | 3   |
| Adverse event, non-fatal     | 1   |
| Pregnancy                    | -   |
| Subject or guardian decision | 1   |
| Lost to follow-up            | -   |
| Lack of efficacy             | 1   |

## Baseline characteristics

### Reporting groups

|                                                            |                   |
|------------------------------------------------------------|-------------------|
| Reporting group title                                      | Secukinumab 150mg |
| Reporting group description:<br>Secukinumab 150mg s.c.     |                   |
| Reporting group title                                      | Secukinumab 300mg |
| Reporting group description:<br>Secukinumab 300mg s.c.     |                   |
| Reporting group title                                      | placebo           |
| Reporting group description:<br>Placebo to secukinumab s.c |                   |

| Reporting group values     | Secukinumab 150mg | Secukinumab 300mg | placebo |
|----------------------------|-------------------|-------------------|---------|
| Number of subjects         | 136               | 272               | 135     |
| Age categorical            |                   |                   |         |
| Based on Induction Period  |                   |                   |         |
| Units: Subjects            |                   |                   |         |
| Adults (< 65)              | 133               | 265               | 133     |
| From 65-84 years           | 3                 | 7                 | 2       |
| 85 years and over          | 0                 | 0                 | 0       |
| Age Continuous             |                   |                   |         |
| Units: years               |                   |                   |         |
| arithmetic mean            | 41                | 39.9              | 40.1    |
| standard deviation         | ± 11.39           | ± 12.35           | ± 11.01 |
| Sex: Female, Male          |                   |                   |         |
| Based on Induction Period  |                   |                   |         |
| Units: Subjects            |                   |                   |         |
| Female                     | 37                | 67                | 27      |
| Male                       | 99                | 205               | 108     |
| Race/Ethnicity, Customized |                   |                   |         |
| Ethnicity                  |                   |                   |         |
| Based on Induction Period  |                   |                   |         |
| Units: Subjects            |                   |                   |         |
| East Asian                 | 109               | 220               | 109     |
| Southeast Asian            | 19                | 32                | 16      |
| South Asian                | 1                 | 0                 | 0       |
| West Asian                 | 0                 | 3                 | 0       |
| other                      | 6                 | 17                | 10      |
| not reported               | 1                 | 0                 | 0       |
| Race/Ethnicity, Customized |                   |                   |         |
| Race                       |                   |                   |         |
| Units: Subjects            |                   |                   |         |
| Caucasian                  | 7                 | 20                | 10      |
| Asian                      | 129               | 252               | 125     |

| Reporting group values | Total |  |  |
|------------------------|-------|--|--|
| Number of subjects     | 543   |  |  |

|                            |     |  |  |
|----------------------------|-----|--|--|
| Age categorical            |     |  |  |
| Based on Induction Period  |     |  |  |
| Units: Subjects            |     |  |  |
| Adults (< 65)              | 531 |  |  |
| From 65-84 years           | 12  |  |  |
| 85 years and over          | 0   |  |  |
| Age Continuous             |     |  |  |
| Units: years               |     |  |  |
| arithmetic mean            |     |  |  |
| standard deviation         | -   |  |  |
| Sex: Female, Male          |     |  |  |
| Based on Induction Period  |     |  |  |
| Units: Subjects            |     |  |  |
| Female                     | 131 |  |  |
| Male                       | 412 |  |  |
| Race/Ethnicity, Customized |     |  |  |
| Ethnicity                  |     |  |  |
| Based on Induction Period  |     |  |  |
| Units: Subjects            |     |  |  |
| East Asian                 | 438 |  |  |
| Southeast Asian            | 67  |  |  |
| South Asian                | 1   |  |  |
| West Asian                 | 3   |  |  |
| other                      | 33  |  |  |
| not reported               | 1   |  |  |
| Race/Ethnicity, Customized |     |  |  |
| Race                       |     |  |  |
| Units: Subjects            |     |  |  |
| Caucasian                  | 37  |  |  |
| Asian                      | 506 |  |  |

## End points

### End points reporting groups

|                                                        |                             |
|--------------------------------------------------------|-----------------------------|
| Reporting group title                                  | Secukinumab 150mg           |
| Reporting group description:                           |                             |
| Secukinumab 150mg s.c.                                 |                             |
| Reporting group title                                  | Secukinumab 300mg           |
| Reporting group description:                           |                             |
| Secukinumab 300mg s.c.                                 |                             |
| Reporting group title                                  | placebo                     |
| Reporting group description:                           |                             |
| Placebo to secukinumab s.c                             |                             |
| Reporting group title                                  | Secukinumab 150mg           |
| Reporting group description:                           |                             |
| Secukinumab 150mg s.c.                                 |                             |
| Reporting group title                                  | Secukinumab 300mg           |
| Reporting group description:                           |                             |
| Secukinumab 300mg s.c.                                 |                             |
| Reporting group title                                  | placebo - placebo           |
| Reporting group description:                           |                             |
| Placebo patients who remained on Placebo after week 12 |                             |
| Reporting group title                                  | Placebo - secukinumab 300mg |
| Reporting group description:                           |                             |
| patients switched to Secukinumab (AIN457) at week 12   |                             |

### Primary: Psoriasis Area and Severity Index (PASI) 75 (multiple imputation)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Psoriasis Area and Severity Index (PASI) 75 (multiple imputation) |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                   |
| <p>Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</p> |                                                                   |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Primary                                                           |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                   |
| Week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                   |

| End point values            | Secukinumab 150mg | Secukinumab 300mg | placebo         |  |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type          | Reporting group   | Reporting group   | Reporting group |  |
| Number of subjects analysed | 136               | 272               | 135             |  |
| Units: participants         | 112               | 254               | 6               |  |

## Statistical analyses

|                                         |                                      |
|-----------------------------------------|--------------------------------------|
| <b>Statistical analysis title</b>       | PASI 75 Secukinumab 150 mg / Placebo |
| Statistical analysis description:       |                                      |
| PASI 75                                 |                                      |
| Comparison groups                       | Secukinumab 150mg v placebo          |
| Number of subjects included in analysis | 271                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           |                                      |
| P-value                                 | < 0.0001                             |
| Method                                  | Regression, Logistic                 |
| Parameter estimate                      | Odds ratio (OR)                      |
| Point estimate                          | 153.94                               |
| Confidence interval                     |                                      |
| level                                   | 95 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | 54.02                                |
| upper limit                             | 438.67                               |

|                                         |                                      |
|-----------------------------------------|--------------------------------------|
| <b>Statistical analysis title</b>       | PASI 75 Secukinumab 300 mg / Placebo |
| Statistical analysis description:       |                                      |
| PASI 75                                 |                                      |
| Comparison groups                       | Secukinumab 300mg v placebo          |
| Number of subjects included in analysis | 407                                  |
| Analysis specification                  | Pre-specified                        |
| Analysis type                           |                                      |
| P-value                                 | < 0.0001                             |
| Method                                  | Regression, Logistic                 |
| Parameter estimate                      | Odds ratio (OR)                      |
| Point estimate                          | 557.98                               |
| Confidence interval                     |                                      |
| level                                   | 95 %                                 |
| sides                                   | 2-sided                              |
| lower limit                             | 187.2                                |
| upper limit                             | 1663.4                               |

## Primary: Investigator`s Global Assessment (IGA) mod 2011 0/1 (multiple imputation)

|                 |                                                                           |
|-----------------|---------------------------------------------------------------------------|
| End point title | Investigator`s Global Assessment (IGA) mod 2011 0/1 (multiple imputation) |
|-----------------|---------------------------------------------------------------------------|

End point description:

Investigator assessed disease using a validated scale (IGA mod 2011) and rate the disease from a score of 0 (clear skin) to 4 (severe disease). result given in terms of count of participants with response in 100 imputations. The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Week 12

| End point values            | Secukinumab 150mg | Secukinumab 300mg | placebo         |  |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type          | Reporting group   | Reporting group   | Reporting group |  |
| Number of subjects analysed | 136               | 272               | 135             |  |
| Units: participants         | 92                | 214               | 4               |  |

## Statistical analyses

|                                   |                      |
|-----------------------------------|----------------------|
| <b>Statistical analysis title</b> | IGA 150 mg / Placebo |
|-----------------------------------|----------------------|

Statistical analysis description:

IGA

|                                         |                             |
|-----------------------------------------|-----------------------------|
| Comparison groups                       | Secukinumab 150mg v placebo |
| Number of subjects included in analysis | 271                         |
| Analysis specification                  | Pre-specified               |
| Analysis type                           |                             |
| P-value                                 | < 0.0001                    |
| Method                                  | Regression, Logistic        |
| Parameter estimate                      | Odds ratio (OR)             |
| Point estimate                          | 75.82                       |
| Confidence interval                     |                             |
| level                                   | 95 %                        |
| sides                                   | 2-sided                     |
| lower limit                             | 25.81                       |
| upper limit                             | 222.72                      |

|                                   |                                  |
|-----------------------------------|----------------------------------|
| <b>Statistical analysis title</b> | IGA Secukinumab 300 mg / Placebo |
|-----------------------------------|----------------------------------|

Statistical analysis description:

IGA

|                   |                             |
|-------------------|-----------------------------|
| Comparison groups | Secukinumab 300mg v placebo |
|-------------------|-----------------------------|

|                                         |                      |
|-----------------------------------------|----------------------|
| Number of subjects included in analysis | 407                  |
| Analysis specification                  | Pre-specified        |
| Analysis type                           |                      |
| P-value                                 | < 0.0001             |
| Method                                  | Regression, Logistic |
| Parameter estimate                      | Odds ratio (OR)      |
| Point estimate                          | 149.71               |
| Confidence interval                     |                      |
| level                                   | 95 %                 |
| sides                                   | 2-sided              |
| lower limit                             | 51.83                |
| upper limit                             | 432.42               |

## Secondary: Psoriasis Area and Severity Index (PASI) 90 (multiple imputation)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Psoriasis Area and Severity Index (PASI) 90 (multiple imputation) |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                   |
| <p>Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</p> |                                                                   |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Secondary                                                         |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                   |
| Week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                   |

| End point values            | Secukinumab 150mg | Secukinumab 300mg | placebo         |  |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type          | Reporting group   | Reporting group   | Reporting group |  |
| Number of subjects analysed | 136               | 272               | 135             |  |
| Units: participants         | 85                | 210               | 2               |  |

## Statistical analyses

|                                   |                                      |
|-----------------------------------|--------------------------------------|
| Statistical analysis title        | PASI 90 Secukinumab 300 mg / Placebo |
| Statistical analysis description: |                                      |
| PASI 90                           |                                      |
| Comparison groups                 | Secukinumab 300mg v placebo          |

|                                         |                      |
|-----------------------------------------|----------------------|
| Number of subjects included in analysis | 407                  |
| Analysis specification                  | Pre-specified        |
| Analysis type                           |                      |
| P-value                                 | < 0.0001             |
| Method                                  | Regression, Logistic |
| Parameter estimate                      | Odds ratio (OR)      |
| Point estimate                          | 246.12               |
| Confidence interval                     |                      |
| level                                   | 95 %                 |
| sides                                   | 2-sided              |
| lower limit                             | 58.41                |
| upper limit                             | 1037.1               |

|                                              |                                      |
|----------------------------------------------|--------------------------------------|
| <b>Statistical analysis title</b>            | PASI 90 Secukinumab 150 mg / Placebo |
| Statistical analysis description:<br>PASI 90 |                                      |
| Comparison groups                            | Secukinumab 150mg v placebo          |
| Number of subjects included in analysis      | 271                                  |
| Analysis specification                       | Pre-specified                        |
| Analysis type                                |                                      |
| P-value                                      | < 0.0001                             |
| Method                                       | Regression, Logistic                 |
| Parameter estimate                           | Odds ratio (OR)                      |
| Point estimate                               | 114.85                               |
| Confidence interval                          |                                      |
| level                                        | 95 %                                 |
| sides                                        | 2-sided                              |
| lower limit                                  | 26.94                                |
| upper limit                                  | 489.59                               |

### **Secondary: efficacy of secukinumab in maintaining PASI 75 response at Week 52 in subjects who were PASI 75 responders at Week 12 (multiple imputation)**

|                 |                                                                                                                                                            |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | efficacy of secukinumab in maintaining PASI 75 response at Week 52 in subjects who were PASI 75 responders at Week 12 (multiple imputation) <sup>[1]</sup> |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 52

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: There were only 4 patients in the placebo arm after week 12, therefore the analyses was not performed

| End point values            | Secukinumab<br>150mg | Secukinumab<br>300mg |  |  |
|-----------------------------|----------------------|----------------------|--|--|
| Subject group type          | Reporting group      | Reporting group      |  |  |
| Number of subjects analysed | 110                  | 242                  |  |  |
| Units: participants         | 94                   | 235                  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: efficacy of secukinumab in maintaining IGA mod 2011 0 or 1 response at Week 52 in subjects who were IGA mod 2011 0 or 1 responders at Week 12 (multiple imputation)

|                 |                                                                                                                                                                                    |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | efficacy of secukinumab in maintaining IGA mod 2011 0 or 1 response at Week 52 in subjects who were IGA mod 2011 0 or 1 responders at Week 12 (multiple imputation) <sup>[2]</sup> |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Investigator assessed disease using a validated scale (IGA mod 2011) and rate the disease from a score of 0 (clear skin) to 4 (severe disease). result given in terms of count of participants with response in 100 imputations. The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 52

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: There were only 4 patients in the placebo arm after week 12, therefore the analyses was not performed

| End point values            | Secukinumab<br>150mg | Secukinumab<br>300mg |  |  |
|-----------------------------|----------------------|----------------------|--|--|
| Subject group type          | Reporting group      | Reporting group      |  |  |
| Number of subjects analysed | 91                   | 206                  |  |  |
| Units: participants         | 65                   | 162                  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: PASI 50/75/90/100 and IGA mod 2011 0 or 1 response over time (multiple imputation)

|                 |                                                         |
|-----------------|---------------------------------------------------------|
| End point title | PASI 50/75/90/100 and IGA mod 2011 0 or 1 response over |
|-----------------|---------------------------------------------------------|

|                                                                                                  |                            |
|--------------------------------------------------------------------------------------------------|----------------------------|
|                                                                                                  | time (multiple imputation) |
| End point description:                                                                           |                            |
| Number (%) of subjects with PASI 50, PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response |                            |
| End point type                                                                                   | Secondary                  |
| End point timeframe:                                                                             |                            |
| week 1, week 12, week 24, week 52                                                                |                            |

| End point values            | Secukinumab<br>150mg | Secukinumab<br>300mg | placebo         | Placebo -<br>secukinumab<br>300mg |
|-----------------------------|----------------------|----------------------|-----------------|-----------------------------------|
| Subject group type          | Reporting group      | Reporting group      | Reporting group | Reporting group                   |
| Number of subjects analysed | 136                  | 272                  | 135             | 129                               |
| Units: participants         |                      |                      |                 |                                   |
| Week 1 IGA 0/1              | 0                    | 1                    | 0               | 0                                 |
| Week 1 PASI 50              | 5                    | 25                   | 1               | 0                                 |
| Week 1 PASI 75              | 0                    | 0                    | 0               | 0                                 |
| Week 1 PASI 90              | 0                    | 0                    | 0               | 0                                 |
| Week 1 PASI 100             | 0                    | 0                    | 0               | 0                                 |
| Week 12 IGA 0/1             | 92                   | 214                  | 4               | 0                                 |
| Week 12 PASI 50             | 130                  | 267                  | 16              | 0                                 |
| Week 12 PASI 75             | 112                  | 254                  | 6               | 0                                 |
| Week 12 PASI 90             | 85                   | 210                  | 2               | 0                                 |
| Week 12 PASI 100            | 28                   | 81                   | 1               | 0                                 |
| Week 16 IGA 0/1             | 100                  | 219                  | 2               | 32                                |
| Week 16 PASI 50             | 134                  | 270                  | 4               | 108                               |
| Week 16 PASI 75             | 124                  | 261                  | 3               | 72                                |
| Week 16 PASI 90             | 98                   | 233                  | 2               | 22                                |
| Week 16 PASI 100            | 39                   | 99                   | 0               | 3                                 |
| Week 24 IGA 0/1             | 91                   | 217                  | 1               | 88                                |
| Week 24 PASI 50             | 135                  | 271                  | 4               | 123                               |
| Week 24 PASI 75             | 123                  | 257                  | 2               | 113                               |
| Week 24 PASI 90             | 93                   | 230                  | 2               | 94                                |
| Week 24 PASI 100            | 47                   | 107                  | 0               | 31                                |
| Week 52 IGA 0/1             | 79                   | 194                  | 0               | 96                                |
| Week 52 PASI 50             | 128                  | 269                  | 4               | 126                               |
| Week 52 PASI 75             | 111                  | 259                  | 4               | 119                               |
| Week 52 PASI 90             | 86                   | 218                  | 1               | 101                               |
| Week 52 PASI 100            | 42                   | 110                  | 1               | 55                                |

## Statistical analyses

No statistical analyses for this end point

## Secondary: American Collage of Rheumatology (ACR) Response 20/50/70

|                 |                                                          |
|-----------------|----------------------------------------------------------|
| End point title | American Collage of Rheumatology (ACR) Response 20/50/70 |
|-----------------|----------------------------------------------------------|

End point description:

Percentage of patients who achieved ACR 20/50/70 at Week 12 and up to Week 52. The subset of

patients who had active PsA at baseline included 7 patients in the secukinumab 150 mg group, 17 patients in the secukinumab 300 mg group and 4 patients in the placebo group. ACR 20, 50 or 70 responses correspond, respectively, to at least 20%, 50% or 70% improvement in comparison with baseline in the number of tender and swollen joint counts, in addition to similar improvements in at least three of five other measure of disability or disease activity

|                           |           |
|---------------------------|-----------|
| End point type            | Secondary |
| End point timeframe:      |           |
| week 12, week 24, week 52 |           |

| End point values            | Secukinumab 150mg | Secukinumab 300mg | placebo         | Placebo - secukinumab 300mg |
|-----------------------------|-------------------|-------------------|-----------------|-----------------------------|
| Subject group type          | Reporting group   | Reporting group   | Reporting group | Reporting group             |
| Number of subjects analysed | 7                 | 17                | 4               | 4                           |
| Units: participants         |                   |                   |                 |                             |
| Week 12 ACR 20              | 4                 | 13                | 0               | 0                           |
| Week 12 ACR 50              | 3                 | 12                | 0               | 0                           |
| Week 12 ACR 70              | 2                 | 6                 | 0               | 0                           |
| Week 24 ACR 20              | 5                 | 14                | 0               | 2                           |
| Week 24 ACR 50              | 4                 | 10                | 0               | 1                           |
| Week 24 ACR 70              | 2                 | 6                 | 0               | 1                           |
| Week 52 ACR 20              | 4                 | 13                | 0               | 3                           |
| Week 52 ACR 50              | 3                 | 11                | 0               | 2                           |
| Week 52 ACR 70              | 2                 | 8                 | 0               | 0                           |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to PASI 75 response up to Week 12

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Time to PASI 75 response up to Week 12 <sup>[3]</sup> |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                       |
| <p>Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</p> |                                                       |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Secondary                                             |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                       |
| week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                       |

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since only 3.7 % of the placebo patients achieved PASI 75 Response by week 12, this was not analysed

| <b>End point values</b>          | Secukinumab<br>150mg | Secukinumab<br>300mg |  |  |
|----------------------------------|----------------------|----------------------|--|--|
| Subject group type               | Reporting group      | Reporting group      |  |  |
| Number of subjects analysed      | 136                  | 272                  |  |  |
| Units: days                      |                      |                      |  |  |
| median (confidence interval 95%) | 57 (51 to 57)        | 55 (29 to 57)        |  |  |

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 21.1 |
|--------------------|------|

### Reporting groups

|                       |               |
|-----------------------|---------------|
| Reporting group title | AIN457 300 mg |
|-----------------------|---------------|

Reporting group description:

AIN457 300 mg

|                       |               |
|-----------------------|---------------|
| Reporting group title | AIN457 150 mg |
|-----------------------|---------------|

Reporting group description:

AIN457 150 mg

|                       |                 |
|-----------------------|-----------------|
| Reporting group title | Any AIN457 dose |
|-----------------------|-----------------|

Reporting group description:

Any AIN457 dose

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Placebo

|                       |                   |
|-----------------------|-------------------|
| Reporting group title | Any AIN457 300 mg |
|-----------------------|-------------------|

Reporting group description:

Any AIN457 300 mg

| Serious adverse events                                              | AIN457 300 mg   | AIN457 150 mg   | Any AIN457 dose  |
|---------------------------------------------------------------------|-----------------|-----------------|------------------|
| Total subjects affected by serious adverse events                   |                 |                 |                  |
| subjects affected / exposed                                         | 9 / 272 (3.31%) | 5 / 136 (3.68%) | 19 / 537 (3.54%) |
| number of deaths (all causes)                                       | 0               | 0               | 0                |
| number of deaths resulting from adverse events                      | 0               | 0               | 0                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                 |                 |                  |
| Colon adenoma                                                       |                 |                 |                  |
| subjects affected / exposed                                         | 0 / 272 (0.00%) | 1 / 136 (0.74%) | 1 / 537 (0.19%)  |
| occurrences causally related to treatment / all                     | 0 / 0           | 1 / 1           | 1 / 1            |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0            |
| Injury, poisoning and procedural complications                      |                 |                 |                  |
| Comminuted fracture                                                 |                 |                 |                  |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Forearm fracture                                |                 |                 |                 |
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Tibia fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vascular disorders                              |                 |                 |                 |
| Deep vein thrombosis                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Diabetic vascular disorder                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders                               |                 |                 |                 |
| Angina unstable                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 1 / 136 (0.74%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Arteriosclerosis coronary artery                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 1 / 136 (0.74%) | 2 / 537 (0.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 1 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Coronary artery disease                         |                 |                 |                 |
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Cerebral infarction                             |                 |                 |                 |
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Diabetic neuropathy                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Eye disorders                                   |                 |                 |                 |
| Diabetic retinopathy                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders                      |                 |                 |                 |
| Crohn's disease                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 1 / 136 (0.74%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Enteritis                                       |                 |                 |                 |
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Haemorrhoids                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Mouth ulceration                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Tooth impacted                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 1 / 136 (0.74%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Hepatobiliary disorders                         |                 |                 |                 |
| Cholecystitis acute                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cholelithiasis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatic mass                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatic steatosis                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin and subcutaneous tissue disorders          |                 |                 |                 |
| Erythrodermic psoriasis                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 1 / 136 (0.74%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psoriasis                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 0 / 537 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal and urinary disorders                     |                 |                 |                 |
| Glomerulonephritis chronic                      |                 |                 |                 |
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nephrolithiasis                                 |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ureterolithiasis                                |                 |                 |                 |
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| Intervertebral disc protrusion                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 0 / 136 (0.00%) | 0 / 537 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Infections and infestations                     |                 |                 |                 |
| Appendicitis                                    |                 |                 |                 |
| subjects affected / exposed                     | 2 / 272 (0.74%) | 0 / 136 (0.00%) | 2 / 537 (0.37%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Bronchitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Erysipelas                                      |                 |                 |                 |
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Peritonitis                                     |                 |                 |                 |
| subjects affected / exposed                     | 1 / 272 (0.37%) | 0 / 136 (0.00%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Tonsillitis                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 272 (0.00%) | 1 / 136 (0.74%) | 1 / 537 (0.19%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

| <b>Serious adverse events</b>                                       | Placebo         | Any AIN457 300 mg |  |
|---------------------------------------------------------------------|-----------------|-------------------|--|
| Total subjects affected by serious adverse events                   |                 |                   |  |
| subjects affected / exposed                                         | 2 / 135 (1.48%) | 14 / 401 (3.49%)  |  |
| number of deaths (all causes)                                       | 0               | 0                 |  |
| number of deaths resulting from adverse events                      | 0               | 0                 |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                 |                   |  |
| Colon adenoma                                                       |                 |                   |  |
| subjects affected / exposed                                         | 0 / 135 (0.00%) | 0 / 401 (0.00%)   |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0             |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0             |  |
| Injury, poisoning and procedural complications                      |                 |                   |  |
| Comminuted fracture                                                 |                 |                   |  |
| subjects affected / exposed                                         | 0 / 135 (0.00%) | 1 / 401 (0.25%)   |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 1             |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0             |  |
| Forearm fracture                                                    |                 |                   |  |
| subjects affected / exposed                                         | 0 / 135 (0.00%) | 1 / 401 (0.25%)   |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 1             |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0             |  |
| Tibia fracture                                                      |                 |                   |  |
| subjects affected / exposed                                         | 0 / 135 (0.00%) | 1 / 401 (0.25%)   |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 1             |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0             |  |
| Vascular disorders                                                  |                 |                   |  |
| Deep vein thrombosis                                                |                 |                   |  |
| subjects affected / exposed                                         | 0 / 135 (0.00%) | 1 / 401 (0.25%)   |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 1             |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0             |  |
| Diabetic vascular disorder                                          |                 |                   |  |
| subjects affected / exposed                                         | 0 / 135 (0.00%) | 1 / 401 (0.25%)   |  |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 1             |  |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0             |  |
| Cardiac disorders                                                   |                 |                   |  |
| Angina unstable                                                     |                 |                   |  |

|                                                 |                 |                 |  |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed                     | 0 / 135 (0.00%) | 0 / 401 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Arteriosclerosis coronary artery                |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Coronary artery disease                         |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Nervous system disorders                        |                 |                 |  |
| Cerebral infarction                             |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Diabetic neuropathy                             |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Eye disorders                                   |                 |                 |  |
| Diabetic retinopathy                            |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Gastrointestinal disorders                      |                 |                 |  |
| Crohn's disease                                 |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 0 / 401 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Enteritis                                       |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |

|                                                 |                 |                 |  |
|-------------------------------------------------|-----------------|-----------------|--|
| Haemorrhoids                                    |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Mouth ulceration                                |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Tooth impacted                                  |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 0 / 401 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Hepatobiliary disorders                         |                 |                 |  |
| Cholecystitis acute                             |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Cholelithiasis                                  |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Hepatic mass                                    |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Hepatic steatosis                               |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Skin and subcutaneous tissue disorders          |                 |                 |  |
| Erythrodermic psoriasis                         |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 0 / 401 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |

|                                                 |                 |                 |  |
|-------------------------------------------------|-----------------|-----------------|--|
| Psoriasis                                       |                 |                 |  |
| subjects affected / exposed                     | 1 / 135 (0.74%) | 0 / 401 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Renal and urinary disorders                     |                 |                 |  |
| Glomerulonephritis chronic                      |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Nephrolithiasis                                 |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Ureterolithiasis                                |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Musculoskeletal and connective tissue disorders |                 |                 |  |
| Intervertebral disc protrusion                  |                 |                 |  |
| subjects affected / exposed                     | 1 / 135 (0.74%) | 0 / 401 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Infections and infestations                     |                 |                 |  |
| Appendicitis                                    |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 2 / 401 (0.50%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 2           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Bronchitis                                      |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Erysipelas                                      |                 |                 |  |

|                                                 |                 |                 |  |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Peritonitis                                     |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 1 / 401 (0.25%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Tonsillitis                                     |                 |                 |  |
| subjects affected / exposed                     | 0 / 135 (0.00%) | 0 / 401 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |

Frequency threshold for reporting non-serious adverse events: 3 %

| <b>Non-serious adverse events</b>                     | AIN457 300 mg      | AIN457 150 mg      | Any AIN457 dose    |
|-------------------------------------------------------|--------------------|--------------------|--------------------|
| Total subjects affected by non-serious adverse events |                    |                    |                    |
| subjects affected / exposed                           | 221 / 272 (81.25%) | 115 / 136 (84.56%) | 427 / 537 (79.52%) |
| Investigations                                        |                    |                    |                    |
| Blood uric acid increased                             |                    |                    |                    |
| subjects affected / exposed                           | 4 / 272 (1.47%)    | 4 / 136 (2.94%)    | 10 / 537 (1.86%)   |
| occurrences (all)                                     | 7                  | 4                  | 14                 |
| C-reactive protein increased                          |                    |                    |                    |
| subjects affected / exposed                           | 11 / 272 (4.04%)   | 7 / 136 (5.15%)    | 20 / 537 (3.72%)   |
| occurrences (all)                                     | 14                 | 9                  | 25                 |
| Gamma-glutamyltransferase increased                   |                    |                    |                    |
| subjects affected / exposed                           | 10 / 272 (3.68%)   | 2 / 136 (1.47%)    | 14 / 537 (2.61%)   |
| occurrences (all)                                     | 14                 | 2                  | 18                 |
| Vascular disorders                                    |                    |                    |                    |
| Hypertension                                          |                    |                    |                    |
| subjects affected / exposed                           | 19 / 272 (6.99%)   | 5 / 136 (3.68%)    | 27 / 537 (5.03%)   |
| occurrences (all)                                     | 20                 | 5                  | 29                 |
| Nervous system disorders                              |                    |                    |                    |
| Headache                                              |                    |                    |                    |
| subjects affected / exposed                           | 10 / 272 (3.68%)   | 4 / 136 (2.94%)    | 14 / 537 (2.61%)   |
| occurrences (all)                                     | 18                 | 5                  | 23                 |

|                                                                                                                                                                                                                                                                                                                    |                                                                                                                 |                                                                                                                |                                                                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| General disorders and administration site conditions<br>Pyrexia<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                | 14 / 272 (5.15%)<br>15                                                                                          | 4 / 136 (2.94%)<br>4                                                                                           | 22 / 537 (4.10%)<br>24                                                                                          |
| Gastrointestinal disorders<br>Diarrhoea<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                        | 31 / 272 (11.40%)<br>40                                                                                         | 13 / 136 (9.56%)<br>23                                                                                         | 55 / 537 (10.24%)<br>81                                                                                         |
| Hepatobiliary disorders<br>Hepatic function abnormal<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                           | 18 / 272 (6.62%)<br>21                                                                                          | 9 / 136 (6.62%)<br>12                                                                                          | 31 / 537 (5.77%)<br>38                                                                                          |
| Respiratory, thoracic and mediastinal disorders<br>Cough<br>subjects affected / exposed<br>occurrences (all)<br><br>Oropharyngeal pain<br>subjects affected / exposed<br>occurrences (all)                                                                                                                         | 17 / 272 (6.25%)<br>18<br><br>25 / 272 (9.19%)<br>33                                                            | 13 / 136 (9.56%)<br>15<br><br>16 / 136 (11.76%)<br>20                                                          | 38 / 537 (7.08%)<br>41<br><br>48 / 537 (8.94%)<br>68                                                            |
| Skin and subcutaneous tissue disorders<br>Eczema<br>subjects affected / exposed<br>occurrences (all)<br><br>Pruritus<br>subjects affected / exposed<br>occurrences (all)<br><br>Psoriasis<br>subjects affected / exposed<br>occurrences (all)<br><br>Urticaria<br>subjects affected / exposed<br>occurrences (all) | 20 / 272 (7.35%)<br>30<br><br>32 / 272 (11.76%)<br>36<br><br>3 / 272 (1.10%)<br>3<br><br>24 / 272 (8.82%)<br>28 | 10 / 136 (7.35%)<br>11<br><br>12 / 136 (8.82%)<br>15<br><br>6 / 136 (4.41%)<br>7<br><br>12 / 136 (8.82%)<br>16 | 35 / 537 (6.52%)<br>46<br><br>48 / 537 (8.94%)<br>56<br><br>9 / 537 (1.68%)<br>10<br><br>42 / 537 (7.82%)<br>51 |
| Musculoskeletal and connective tissue disorders<br>Arthralgia<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                  | 11 / 272 (4.04%)<br>13                                                                                          | 4 / 136 (2.94%)<br>5                                                                                           | 16 / 537 (2.98%)<br>19                                                                                          |

|                                           |                   |                   |                    |
|-------------------------------------------|-------------------|-------------------|--------------------|
| <b>Infections and infestations</b>        |                   |                   |                    |
| Folliculitis                              |                   |                   |                    |
| subjects affected / exposed               | 18 / 272 (6.62%)  | 6 / 136 (4.41%)   | 32 / 537 (5.96%)   |
| occurrences (all)                         | 23                | 6                 | 38                 |
| Influenza                                 |                   |                   |                    |
| subjects affected / exposed               | 28 / 272 (10.29%) | 17 / 136 (12.50%) | 55 / 537 (10.24%)  |
| occurrences (all)                         | 47                | 31                | 101                |
| Nasopharyngitis                           |                   |                   |                    |
| subjects affected / exposed               | 44 / 272 (16.18%) | 15 / 136 (11.03%) | 72 / 537 (13.41%)  |
| occurrences (all)                         | 59                | 18                | 92                 |
| Pharyngitis                               |                   |                   |                    |
| subjects affected / exposed               | 24 / 272 (8.82%)  | 14 / 136 (10.29%) | 49 / 537 (9.12%)   |
| occurrences (all)                         | 34                | 22                | 69                 |
| Rhinitis                                  |                   |                   |                    |
| subjects affected / exposed               | 14 / 272 (5.15%)  | 2 / 136 (1.47%)   | 18 / 537 (3.35%)   |
| occurrences (all)                         | 14                | 4                 | 20                 |
| Tinea pedis                               |                   |                   |                    |
| subjects affected / exposed               | 20 / 272 (7.35%)  | 5 / 136 (3.68%)   | 30 / 537 (5.59%)   |
| occurrences (all)                         | 23                | 6                 | 34                 |
| Tonsillitis                               |                   |                   |                    |
| subjects affected / exposed               | 14 / 272 (5.15%)  | 5 / 136 (3.68%)   | 21 / 537 (3.91%)   |
| occurrences (all)                         | 16                | 5                 | 23                 |
| Upper respiratory tract infection         |                   |                   |                    |
| subjects affected / exposed               | 67 / 272 (24.63%) | 41 / 136 (30.15%) | 138 / 537 (25.70%) |
| occurrences (all)                         | 98                | 67                | 208                |
| <b>Metabolism and nutrition disorders</b> |                   |                   |                    |
| Dyslipidaemia                             |                   |                   |                    |
| subjects affected / exposed               | 2 / 272 (0.74%)   | 0 / 136 (0.00%)   | 2 / 537 (0.37%)    |
| occurrences (all)                         | 2                 | 0                 | 2                  |
| Hyperlipidaemia                           |                   |                   |                    |
| subjects affected / exposed               | 22 / 272 (8.09%)  | 11 / 136 (8.09%)  | 34 / 537 (6.33%)   |
| occurrences (all)                         | 22                | 11                | 34                 |
| Hyperuricaemia                            |                   |                   |                    |
| subjects affected / exposed               | 56 / 272 (20.59%) | 25 / 136 (18.38%) | 101 / 537 (18.81%) |
| occurrences (all)                         | 85                | 35                | 148                |

|                                   |         |                   |  |
|-----------------------------------|---------|-------------------|--|
| <b>Non-serious adverse events</b> | Placebo | Any AIN457 300 mg |  |
|-----------------------------------|---------|-------------------|--|

|                                                                                      |                   |                    |  |
|--------------------------------------------------------------------------------------|-------------------|--------------------|--|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed | 71 / 135 (52.59%) | 312 / 401 (77.81%) |  |
| Investigations                                                                       |                   |                    |  |
| Blood uric acid increased<br>subjects affected / exposed                             | 5 / 135 (3.70%)   | 6 / 401 (1.50%)    |  |
| occurrences (all)                                                                    | 5                 | 10                 |  |
| C-reactive protein increased<br>subjects affected / exposed                          | 3 / 135 (2.22%)   | 13 / 401 (3.24%)   |  |
| occurrences (all)                                                                    | 3                 | 16                 |  |
| Gamma-glutamyltransferase increased<br>subjects affected / exposed                   | 1 / 135 (0.74%)   | 12 / 401 (2.99%)   |  |
| occurrences (all)                                                                    | 1                 | 16                 |  |
| Vascular disorders                                                                   |                   |                    |  |
| Hypertension<br>subjects affected / exposed                                          | 4 / 135 (2.96%)   | 22 / 401 (5.49%)   |  |
| occurrences (all)                                                                    | 4                 | 24                 |  |
| Nervous system disorders                                                             |                   |                    |  |
| Headache<br>subjects affected / exposed                                              | 2 / 135 (1.48%)   | 10 / 401 (2.49%)   |  |
| occurrences (all)                                                                    | 4                 | 18                 |  |
| General disorders and administration site conditions                                 |                   |                    |  |
| Pyrexia<br>subjects affected / exposed                                               | 1 / 135 (0.74%)   | 18 / 401 (4.49%)   |  |
| occurrences (all)                                                                    | 1                 | 20                 |  |
| Gastrointestinal disorders                                                           |                   |                    |  |
| Diarrhoea<br>subjects affected / exposed                                             | 12 / 135 (8.89%)  | 42 / 401 (10.47%)  |  |
| occurrences (all)                                                                    | 28                | 58                 |  |
| Hepatobiliary disorders                                                              |                   |                    |  |
| Hepatic function abnormal<br>subjects affected / exposed                             | 4 / 135 (2.96%)   | 22 / 401 (5.49%)   |  |
| occurrences (all)                                                                    | 4                 | 26                 |  |
| Respiratory, thoracic and mediastinal disorders                                      |                   |                    |  |
| Cough<br>subjects affected / exposed                                                 | 2 / 135 (1.48%)   | 25 / 401 (6.23%)   |  |
| occurrences (all)                                                                    | 2                 | 26                 |  |
| Oropharyngeal pain                                                                   |                   |                    |  |

|                                                  |                      |                        |  |
|--------------------------------------------------|----------------------|------------------------|--|
| subjects affected / exposed<br>occurrences (all) | 3 / 135 (2.22%)<br>3 | 32 / 401 (7.98%)<br>48 |  |
| Skin and subcutaneous tissue disorders           |                      |                        |  |
| Eczema                                           |                      |                        |  |
| subjects affected / exposed                      | 0 / 135 (0.00%)      | 25 / 401 (6.23%)       |  |
| occurrences (all)                                | 0                    | 35                     |  |
| Pruritus                                         |                      |                        |  |
| subjects affected / exposed                      | 11 / 135 (8.15%)     | 36 / 401 (8.98%)       |  |
| occurrences (all)                                | 13                   | 41                     |  |
| Psoriasis                                        |                      |                        |  |
| subjects affected / exposed                      | 0 / 135 (0.00%)      | 3 / 401 (0.75%)        |  |
| occurrences (all)                                | 0                    | 3                      |  |
| Urticaria                                        |                      |                        |  |
| subjects affected / exposed                      | 0 / 135 (0.00%)      | 30 / 401 (7.48%)       |  |
| occurrences (all)                                | 0                    | 35                     |  |
| Musculoskeletal and connective tissue disorders  |                      |                        |  |
| Arthralgia                                       |                      |                        |  |
| subjects affected / exposed                      | 3 / 135 (2.22%)      | 12 / 401 (2.99%)       |  |
| occurrences (all)                                | 3                    | 14                     |  |
| Infections and infestations                      |                      |                        |  |
| Folliculitis                                     |                      |                        |  |
| subjects affected / exposed                      | 0 / 135 (0.00%)      | 26 / 401 (6.48%)       |  |
| occurrences (all)                                | 0                    | 32                     |  |
| Influenza                                        |                      |                        |  |
| subjects affected / exposed                      | 4 / 135 (2.96%)      | 38 / 401 (9.48%)       |  |
| occurrences (all)                                | 5                    | 70                     |  |
| Nasopharyngitis                                  |                      |                        |  |
| subjects affected / exposed                      | 5 / 135 (3.70%)      | 57 / 401 (14.21%)      |  |
| occurrences (all)                                | 5                    | 74                     |  |
| Pharyngitis                                      |                      |                        |  |
| subjects affected / exposed                      | 7 / 135 (5.19%)      | 35 / 401 (8.73%)       |  |
| occurrences (all)                                | 13                   | 47                     |  |
| Rhinitis                                         |                      |                        |  |
| subjects affected / exposed                      | 1 / 135 (0.74%)      | 16 / 401 (3.99%)       |  |
| occurrences (all)                                | 1                    | 16                     |  |
| Tinea pedis                                      |                      |                        |  |

|                                    |                   |                   |  |
|------------------------------------|-------------------|-------------------|--|
| subjects affected / exposed        | 1 / 135 (0.74%)   | 25 / 401 (6.23%)  |  |
| occurrences (all)                  | 1                 | 28                |  |
| Tonsillitis                        |                   |                   |  |
| subjects affected / exposed        | 1 / 135 (0.74%)   | 16 / 401 (3.99%)  |  |
| occurrences (all)                  | 1                 | 18                |  |
| Upper respiratory tract infection  |                   |                   |  |
| subjects affected / exposed        | 13 / 135 (9.63%)  | 97 / 401 (24.19%) |  |
| occurrences (all)                  | 14                | 141               |  |
| Metabolism and nutrition disorders |                   |                   |  |
| Dyslipidaemia                      |                   |                   |  |
| subjects affected / exposed        | 5 / 135 (3.70%)   | 2 / 401 (0.50%)   |  |
| occurrences (all)                  | 5                 | 2                 |  |
| Hyperlipidaemia                    |                   |                   |  |
| subjects affected / exposed        | 11 / 135 (8.15%)  | 23 / 401 (5.74%)  |  |
| occurrences (all)                  | 11                | 23                |  |
| Hyperuricaemia                     |                   |                   |  |
| subjects affected / exposed        | 17 / 135 (12.59%) | 76 / 401 (18.95%) |  |
| occurrences (all)                  | 18                | 113               |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date         | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 09 June 2017 | The aim of this amendment was to introduce a provision for a Week 16 analysis. This analysis included primary endpoint data at Week 12 and in addition data at Week 16 visit. This amendment also introduced the provision for additional subsequent interim analyses that may be conducted to fulfill any request from Health Authorities. In addition, this amendment was used to clarify minor inconsistencies between various protocol sections, and correct minor errors; these did not affect the study design or population. |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported